

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Journal of Rehabilitation Medicine

Table SI. Characteristics and Baseline Results of Participants Stratified by Gender

Descriptor		Female	Male	Standardized Difference	P-Value
Group, n (%)				0.05 (-0.31, 0.41)	0.790
	Intervention	32 (48.48%)	27 (50.94%)		
	Control	34 (51.52%)	26 (49.06%)		
Age in years, mean (SD)		50.52 (10.18)	50.74 (11.99)	0.02 (-0.34, 0.38)	0.914
In-hospital treatment modalities					
Days from onset to admission, Median (IQR)		5.00 (2.00-9.00)	6.00 (2.00-8.00)	0.20 (-0.17, 0.56)	0.606
Disease severity [†] , n (%)				0.37 (0.01, 0.74)	0.045
	Not severe	50 (75.76%)	31 (58.49%)		
	Severe	16 (24.24%)	22 (41.51%)		
Oxygen support or non-invasive ventilation, n (%)				0.22 (-0.15, 0.58)	0.250
	Yes	55 (83.33%)	48 (90.57%)		
Treatment with corticosteroids, n (%)				0.66 (0.29, 1.04)	<0.001
	Yes	18 (27.27%)	31 (58.49%)		
Length of inpatient stay, Median (IQR)		21.00 (14.00-28.75)	24.00 (17.00-38.00)	0.35 (-0.01, 0.72)	0.060
Medical history (baseline)					
Comorbidity presence, n (%)				0.40 (0.03, 0.76)	0.111
	None	31 (46.97%)	15 (28.30%)		
	Single	21 (31.82%)	24 (45.28%)		

	Multi	14 (21.21%)	14 (26.42%)		
Comorbidity types, n (%)					
	Heart disease	3 (4.55%)	6 (11.32%)	0.25 (-0.11, 0.62)	0.165
	Hypertension	9 (13.64%)	17 (32.08%)	0.45 (0.08, 0.82)	0.016
	Diabetes	4 (6.06%)	13 (24.53%)	0.53 (0.16, 0.90)	0.004
	Obesity	10 (15.15%)	7 (13.21%)	0.06 (-0.31, 0.42)	0.763
	Lung disease (including inactive TB)	6 (9.09%)	1 (1.89%)	0.32 (-0.04, 0.68)	0.097
	Other comorbidity	17 (25.76%)	11 (20.75%)	0.12 (-0.24, 0.48)	0.523
Smoking history, n (%)				0.89 (0.51, 1.27)	<0.001
	Yes	0 (0.00%)	15 (28.30%)		
Trial information					
Days from hospital discharge to baseline, mean (SD)		69.35 (16.66)	70.96 (17.21)	0.10 (-0.27, 0.46)	0.606
Days from baseline to post-treatment assessment, mean (SD)		42.78 (1.91)	42.96 (2.38)	0.08 (-0.29, 0.46)	0.663
Days from baseline to follow-up assessment, mean (SD)		198.13 (7.78)	196.07 (9.23)	0.24 (-0.15, 0.63)	0.221
Outcomes (baseline)					
6MWD (m), mean (SD)		479.56 (84.75)	541.58 (80.81)	0.75 (0.38, 1.12)	<0.001
Squat time (s), Median (IQR)		28.00 (17.25-39.00)	38.00 (28.00-59.00)	0.56 (0.20, 0.93)	0.002
Spirometry					
FEV1 (L), mean (SD)		2.32 (0.49)	3.35 (0.80)	1.55 (1.13, 1.97)	<0.001
FEV1 (% predicted), mean (SD)		77.38 (17.56)	80.02 (15.96)	0.16 (-0.21, 0.53)	0.408
FEV1 below LLN, n (%)		28 (43.08%)	22 (44.00%)	0.02 (-0.35, 0.39)	0.921

FVC (L), mean (SD)		2.32 (0.49)	3.35 (0.80)	1.55 (1.13, 1.97)	<0.001
FVC (% predicted), mean (SD)		81.71 (14.97)	82.46 (15.65)	0.05 (-0.32, 0.42)	0.794
FVC below LLN, n (%)		26 (40.00%)	19 (38.00%)	0.04 (-0.33, 0.41)	0.828
FEV1/FVC		0.79 (0.14)	0.80 (0.12)	0.06 (-0.31, 0.42)	0.773
FEV1/FVC (% predicted), mean (SD)		95.30 (17.06)	97.90 (14.37)	0.16 (-0.20, 0.53)	0.389
FEV1/FVC below LLN, n (%)		16 (24.62%)	10 (20.00%)	0.11 (-0.26, 0.48)	0.557
MVV (L/min), Median (IQR)		55.65 (45.60-67.33)	80.78 (59.34-108.40)	1.03 (0.64, 1.42)	<0.001
MVV (% predicted), Median (IQR)		60.87 (50.78-73.23)	61.56 (42.83-75.95)	0.04 (-0.33, 0.41)	0.748
PEF (L/s), mean (SD)		3.01 (1.31)	5.14 (2.26)	1.15 (0.76, 1.55)	<0.001
PEF (% predicted) , Median (IQR)		43.19 (33.14-53.38)	52.98 (32.83-70.91)	0.36 (-0.01, 0.73)	0.056
SF-12 PCS, mean (SD)		38.17 (7.05)	40.99 (6.88)	0.40 (0.04, 0.77)	0.031
SF-12 MCS, mean (SD)		42.52 (8.60)	46.74 (7.79)	0.51 (0.15, 0.88)	0.006
mMRC-dyspnoea, n (%)				0.35 (-0.02, 0.71)	0.050
	2‡	66 (100.00%)	50 (94.34%)		
	3§	0 (0.00%)	3 (5.66%)		

SD, standard deviation; IQR, interquartile range

† Cases were defined as severe when patients met one of the following criteria at any time during hospitalisation: acute respiratory distress, respiratory rate ≥ 30 breath/min; pulse oxygen saturation (SpO₂) $\leq 93\%$ at rest; arterial blood partial pressure of oxygen/fraction of inspired oxygen (PaO₂/FiO₂) ≤ 300 mm Hg (1 mm Hg=0.133 kPa); respiratory failure requiring mechanical ventilation; septic shock; failure of other organs requiring intensive care unit treatment.

‡ On level ground, walks slower than people of same age because of breathlessness or has to stop for breath when walking at own pace.

§ Stops for breath after walking about 100 yards or after a few minutes on level ground.

Table SII. Characteristics and Baseline Results of Participants Stratified by Disease Severity

Descriptor		Not severe	Severe	Standardized Difference	P-Value
Group, n (%)				0.25 (-0.14, 0.63)	0.214
	Intervention	37 (45.68%)	22 (57.89%)		
	Control	44 (54.32%)	16 (42.11%)		
Gender, n (%)				0.40 (0.01, 0.79)	0.045
	Male	50 (61.73%)	16 (42.11%)		
	Female	31 (38.27%)	22 (57.89%)		
Age in years, mean (SD)		50.46 (11.12)	50.95 (10.79)	0.05 (-0.34, 0.43)	0.820
In-hospital treatment modalities					
Days from onset to admission, Median (IQR)		5.50 (2.00-9.00)	5.00 (1.00-8.00)	0.38 (-0.01, 0.77)	0.141
Oxygen support or non-invasive ventilation, n (%)				0.70 (0.31, 1.10)	0.003
	Yes	65 (80.25%)	38 (100.00%)		
Treatment with corticosteroids, n (%)				1.82 (1.37, 2.27)	<0.001
	Yes	16 (19.75%)	33 (86.84%)		
Length of inpatient stay, Median (IQR)		21.00 (15.00-28.00)	27.50 (19.50-41.00)	0.62 (0.22, 1.01)	0.003
Medical history (baseline)					
Comorbidity presence, n (%)				0.10 (-0.29, 0.48)	0.884
	None	32 (39.51%)	14 (36.84%)		
	Single	31 (38.27%)	14 (36.84%)		
	Multi	18 (22.22%)	10 (26.32%)		
Comorbidity types, n (%)					

	Heart disease	8 (9.88%)	1 (2.63%)	0.30 (-0.08, 0.69)	0.163
	Hypertension	15 (18.52%)	11 (28.95%)	0.25 (-0.14, 0.63)	0.199
	Diabetes	9 (11.11%)	8 (21.05%)	0.27 (-0.11, 0.66)	0.148
	Obesity	12 (14.81%)	5 (13.16%)	0.05 (-0.34, 0.43)	0.810
	Lung disease (including inactive TB)	4 (4.94%)	3 (7.89%)	0.12 (-0.26, 0.51)	0.523
	Other comorbidity	21 (25.93%)	7 (18.42%)	0.18 (-0.20, 0.57)	0.368
Smoking history, n (%)					
	Yes	9 (11.11%)	6 (15.79%)	0.14 (-0.25, 0.52)	0.473
Trial information					
Days from hospital discharge to baseline, mean (SD)		70.96 (16.80)	68.16 (17.04)	0.17 (-0.22, 0.55)	0.400
Days from baseline to post-treatment assessment, mean (SD)		42.91 (1.85)	42.74 (2.67)	0.08 (-0.33, 0.48)	0.690
Days from baseline to follow-up assessment, mean (SD)		197.48 (7.85)	196.94 (9.58)	0.06 (-0.35, 0.47)	0.761
Outcomes (baseline)					
6MWD (m), mean (SD)		509.56 (82.91)	502.13 (99.74)	0.08 (-0.30, 0.47)	0.671
Squat time (s), Median (IQR)		34.00 (23.00-55.00)	28.50 (15.25-38.00)	0.35 (-0.03, 0.74)	0.025
Spirometry					
FEV1 (L), mean (SD)		2.75 (0.89)	2.81 (0.65)	0.08 (-0.31, 0.47)	0.712
FEV1 (% predicted), mean (SD)		78.76 (17.52)	78.07 (15.66)	0.04 (-0.35, 0.43)	0.838
FEV1 below LLN, n (%)		31 (40.26%)	19 (50.00%)	0.20 (-0.19, 0.59)	0.322
FVC (L), mean (SD)		2.75 (0.89)	2.81 (0.65)	0.08 (-0.31, 0.47)	0.712
FVC (% predicted), mean (SD)		83.15 (15.68)	79.78 (14.12)	0.23 (-0.16, 0.62)	0.265

FVC below LLN, n (%)		28 (36.36%)	17 (44.74%)	0.17 (-0.22, 0.56)	0.387
FEV1/FVC		0.81 (0.09)	0.82 (0.08)	0.08 (-0.34, 0.50)	0.720
FEV1/FVC (% predicted), mean (SD)		95.45 (16.54)	98.43 (14.62)	0.19 (-0.20, 0.58)	0.347
FEV1/FVC below LLN, n (%)		20 (25.97%)	6 (15.79%)	0.25 (-0.14, 0.64)	0.219
MVV (L/min), Median (IQR)		60.85 (47.92-78.91)	62.84 (53.12-98.94)	0.41 (0.02, 0.80)	0.147
MVV (% predicted), Median (IQR)		61.48 (45.93-72.75)	60.54 (47.34-77.86)	0.12 (-0.27, 0.51)	0.682
PEF (L/s), mean (SD)		3.63 (1.82)	4.55 (2.41)	0.43 (0.03, 0.82)	0.025
PEF (% predicted) , Median (IQR)		43.73 (33.14-59.60)	44.24 (33.09-69.21)	0.28 (-0.11, 0.67)	0.415
SF-12 PCS, mean (SD)		39.80 (7.16)	38.63 (6.97)	0.17 (-0.22, 0.55)	0.404
SF-12 MCS, mean (SD)		43.54 (8.25)	46.24 (8.78)	0.32 (-0.07, 0.70)	0.106
mMRC-dyspnoea, n (%)				0.01 (-0.38, 0.40)	0.958
	2‡	79 (97.53%)	37 (97.37%)		
	3§	2 (2.47%)	1 (2.63%)		

SD, standard deviation; IQR, interquartile range

†Cases were defined as severe when patients met one of the following criteria at any time during hospitalisation: acute respiratory distress, respiratory rate ≥ 30 breath/min; pulse oxygen saturation (SpO₂) $\leq 93\%$ at rest; arterial blood partial pressure of oxygen/fraction of inspired oxygen (PaO₂/FiO₂) ≤ 300 mm Hg (1 mm Hg=0.133 kPa); respiratory failure requiring mechanical ventilation; septic shock; failure of other organs requiring intensive care unit treatment.

‡ On level ground, walks slower than people of same age because of breathlessness or has to stop for breath when walking at own pace.

§ Stops for breath after walking about 100 yards or after a few minutes on level ground.

Table III. Characteristics and Baseline Results of Participants Stratified by Corticosteroid Usage

Descriptor		Treatment with corticosteroids		Standardized Difference	P-Value
		No	Yes		
Group, n (%)				0.12 (-0.25, 0.48)	0.525
	Intervention	33 (47.14%)	26 (53.06%)		
	Control	37 (52.86%)	23 (46.94%)		
Gender, n (%)				0.67 (0.30, 1.05)	<0.001
	Male	48 (68.57%)	18 (36.73%)		
	Female	22 (31.43%)	31 (63.27%)		
Age in years, mean (SD)		49.20 (10.64)	52.63 (11.24)	0.31 (-0.05, 0.68)	0.094
In-hospital treatment modalities					
Days from onset to admission, Median (IQR)		6.00 (3.00-9.00)	4.00 (1.00-8.00)	0.43 (0.06, 0.80)	0.092
Disease severity†, n (%)				1.59 (1.17, 2.01)	<0.001
	Not severe	65 (92.86%)	16 (32.65%)		
	Severe	5 (7.14%)	33 (67.35%)		
Oxygen support or non-invasive ventilation, n (%)				0.77 (0.39, 1.15)	<0.001
	Yes	54 (77.14%)	49 (100.00%)		
Length of inpatient stay, Median (IQR)		20.50 (14.25-27.50)	26.00 (19.00-41.00)	0.54 (0.16, 0.91)	0.006
Medical history (baseline)					
Comorbidity presence, n (%)				0.29 (-0.08, 0.66)	0.295
	None	28 (40.00%)	18 (36.73%)		

	Single	29 (41.43%)	16 (32.65%)		
	Multi	13 (18.57%)	15 (30.61%)		
Comorbidity types, n (%)					
	Heart disease	6 (8.57%)	3 (6.12%)	0.09 (-0.27, 0.46)	0.619
	Hypertension	11 (15.71%)	15 (30.61%)	0.36 (-0.01, 0.73)	0.053
	Diabetes	6 (8.57%)	11 (22.45%)	0.39 (0.02, 0.76)	0.033
	Obesity	10 (14.29%)	7 (14.29%)	0.00 (-0.37, 0.37)	1.000
	Lung disease (including inactive TB)	5 (7.14%)	2 (4.08%)	0.13 (-0.23, 0.50)	0.485
	Other comorbidity	17 (24.29%)	11 (22.45%)	0.04 (-0.32, 0.41)	0.816
Smoking history, n (%)					
	Yes	8 (11.43%)	7 (14.29%)		
Trial information					
Days from hospital discharge to baseline, mean (SD)		70.71 (16.37)	69.14 (17.66)	0.09 (-0.27, 0.46)	0.619
Days from baseline to post-treatment assessment, mean (SD)		43.08 (2.30)	42.54 (1.80)	0.26 (-0.12, 0.64)	0.192
Days from baseline to follow-up assessment, mean (SD)		197.42 (7.49)	197.14 (9.67)	0.03 (-0.36, 0.42)	0.868
Outcomes (baseline)					
6MWD (m), mean (SD)		511.57 (76.28)	500.92 (103.55)	0.12 (-0.25, 0.48)	0.519
Squat time (s), Median (IQR)		33.50 (22.00-49.50)	31.00 (17.00-45.00)	0.07 (-0.29, 0.44)	0.373
Spirometry					
FEV1 (L), mean (SD)		2.13 (0.72)	2.27 (0.70)	0.20 (-0.18, 0.57)	0.304
FEV1 (% predicted), mean (SD)		78.99 (16.17)	77.89 (17.93)	0.06 (-0.31, 0.44)	0.731

FEV1 below LLN, n (%)		28 (41.79%)	22 (45.83%)	0.08 (-0.29, 0.45)	0.666
FVC (L), mean (SD)		2.69 (0.86)	2.88 (0.75)	0.23 (-0.15, 0.60)	0.239
FVC (% predicted), mean (SD)		82.54 (15.55)	81.34 (14.84)	0.08 (-0.29, 0.45)	0.680
FVC below LLN, n (%)		26 (38.81%)	19 (39.58%)	0.02 (-0.35, 0.39)	0.933
FEV1/FVC		0.80 (0.13)	0.79 (0.14)	0.10 (-0.27, 0.47)	0.595
FEV1/FVC (% predicted), mean (SD)		96.63 (15.54)	96.16 (16.61)	0.03 (-0.34, 0.40)	0.877
FEV1/FVC below LLN, n (%)		15 (22.39%)	11 (22.92%)	0.01 (-0.36, 0.38)	0.947
MVV (L/min), Median (IQR)		60.85 (47.55-78.66)	62.84 (48.59-100.01)	0.33 (-0.04, 0.71)	0.240
MVV (% predicted), Median (IQR)		61.64 (51.02-72.39)	60.14 (42.47-79.31)	0.05 (-0.32, 0.42)	0.772
PEF (L/s), mean (SD)		3.50 (1.77)	4.54 (2.32)	0.51 (0.13, 0.88)	0.007
PEF (% predicted) , Median (IQR)		42.27 (32.89-58.94)	46.66 (34.19-69.75)	0.32 (-0.05, 0.69)	0.221
SF-12 PCS, mean (SD)		39.96 (7.46)	38.66 (6.51)	0.18 (-0.18, 0.55)	0.330
SF-12 MCS, mean (SD)		43.00 (8.64)	46.40 (7.91)	0.41 (0.04, 0.78)	0.031
mMRC-dyspnoea, n (%)				0.16 (-0.20, 0.53)	0.364
	2‡	69 (98.57%)	47 (95.92%)		
	3§	1 (1.43%)	2 (4.08%)		

SD, standard deviation; IQR, interquartile range

†Cases were defined as severe when patients met one of the following criteria at any time during hospitalisation: acute respiratory distress, respiratory rate ≥ 30 breath/min; pulse oxygen saturation (SpO₂) $\leq 93\%$ at rest; arterial blood partial pressure of oxygen/fraction of inspired oxygen (PaO₂/FiO₂) ≤ 300 mm Hg (1 mm Hg=0.133 kPa); respiratory failure requiring mechanical ventilation; septic shock; failure of other organs requiring intensive care unit treatment.

‡ On level ground, walks slower than people of same age because of breathlessness or has to stop for breath when walking at own pace.

§ Stops for breath after walking about 100 yards or after a few minutes on level ground.

Table SIV. Analysis of Posterior Probabilities under 2 Class

Class	1	2
1	0.992 (0.816 - 1.000)	0.030 (<0.001 - 0.357)
2	0.008 (<0.001 - 0.184)	0.970 (0.643 - 1.000)

Table SV. Analysis of Posterior Probabilities under 3 Class

Class	1	2	3
1	0.999 (0.995 - 1.000)	<0.001 (<0.001 - 0.003)	0.001 (<0.001 - 0.015)
2	<0.001 (<0.001 - <0.001)	0.984 (0.621 - 1.000)	0.010 (<0.000 - 0.287)
3	<0.001 (<0.001 - 0.005)	0.016 (<0.001 - 0.379)	0.989 (0.713 - 1.000)

Table SVI. Analysis of Posterior Probabilities under 4 Class

Class	1	2	3	4
1	0.980 (0.634 - 1.000)	<0.001 (<0.001 - <0.001)	<0.001 (<0.001 - <0.001)	0.004 (<0.000 - 0.052)
2	0.013 (<0.001 - 0.293)	0.997 (0.954 - 1.000)	0.002 (<0.001 - 0.030)	<0.001 (<0.001 - <0.001)
3	0.001 (<0.001 - 0.018)	0.003 (<0.001 - 0.047)	0.989 (0.808 - 1.000)	0.014 (<0.001 - 0.412)
4	0.007 (<0.001 - 0.162)	<0.001 (<0.001 - <0.001)	0.009 (<0.001 - 0.192)	0.982 (0.588 - 1.000)

Table SVII. Values of Key Subphenotype-Defining Variables At Participant characteristics Baseline, Stratified by Subphenotype

Descriptor		PHENOTYPE 1	PHENOTYPE 2	P-Value
Group, n (%)				0.650
	Intervention	30 (47.62%)	29 (51.79%)	
	Control	33 (52.38%)	27 (48.21%)	
Age in years, mean (SD)		53.77 (8.97)	47.06 (11.98)	<0.001
Gender, n (%)				<0.001
	Male	19 (30.16%)	34 (60.71%)	
	Female	44 (69.84%)	22 (39.29%)	
In-hospital treatment modalities				
Days from onset to admission, Median (IQR)		4.50 (1.25-9.00)	6.00 (3.00-8.25)	0.352
Disease severity†, n (%)				0.660
	Not severe	44 (69.84%)	37 (66.07%)	
	Severe	19 (30.16%)	19 (33.93%)	
Oxygen support or non-invasive ventilation, n (%)				0.429
	Yes	56 (88.89%)	47 (83.93%)	
Treatment with corticosteroids, n (%)				0.469
	Yes	24 (38.10%)	25 (44.64%)	
Length of inpatient stay, Median (IQR)		21.00 (15.00-29.00)	23.50 (16.00-37.00)	0.336
Medical history (baseline)				
Comorbidity presence, n (%)				0.252

	None	20 (31.75%)	26 (46.43%)	
	Single	26 (41.27%)	19 (33.93%)	
	Multi	17 (26.98%)	11 (19.64%)	
Comorbidity types, n (%)				
	Heart disease	6 (9.52%)	3 (5.36%)	0.391
	Hypertension	17 (26.98%)	9 (16.07%)	0.150
	Diabetes	10 (15.87%)	7 (12.50%)	0.600
	Obesity	7 (11.11%)	10 (17.86%)	0.294
	Lung disease (including inactive TB)	4 (6.35%)	3 (5.36%)	0.818
	Other comorbidity	18 (28.57%)	10 (17.86%)	0.169
Smoking history, n (%)				
	Yes	6 (9.52%)	9 (16.07%)	
Trial information				
Days from hospital discharge to baseline, mean (SD)		69.84 (18.83)	70.32 (14.47)	0.877
Days from baseline to post-treatment assessment, mean (SD)		42.53 (1.61)	43.23 (2.55)	0.082
Days from baseline to follow-up assessment, mean (SD)		197.55 (7.52)	197.02 (9.39)	0.747

SD, standard deviation; IQR, interquartile range

†Cases were defined as severe when patients met one of the following criteria at any time during hospitalisation: acute respiratory distress, respiratory rate ≥ 30 breath/min; pulse oxygen saturation (SpO₂) $\leq 93\%$ at rest; arterial blood partial pressure of oxygen/fraction of inspired oxygen (PaO₂/FiO₂) ≤ 300 mm Hg (1 mm Hg=0.133 kPa); respiratory failure requiring mechanical ventilation; septic shock; failure of other organs requiring intensive care unit treatment.

Table SVIII. Values of Key Subphenotype-Defining Variables At Outcomes (baseline), Stratified by Subphenotype

Descriptor		PHENOTYPE 1	PHENOTYPE 2	P-Value
6MWD (m), mean (SD)		493.76 (76.07)	522.29 (98.77)	0.078
Squat time (s), Median (IQR)		28.00 (18.00-38.00)	37.50 (27.00-59.25)	0.002
Spirometry				
FEV1 (L), mean (SD)		1.75 (0.45)	2.73 (0.60)	<0.001
FEV1 (% predicted), mean (SD)		68.94 (13.12)	90.15 (13.22)	<0.001
FEV1 below LLN, n (%)		42 (66.67%)	8 (15.38%)	<0.001
FVC (L), mean (SD)		2.39 (0.70)	3.23 (0.71)	<0.001
FVC (% predicted), mean (SD)		76.81 (14.51)	88.37 (13.64)	<0.001
FVC below LLN, n (%)		35 (55.56%)	10 (19.23%)	<0.001
FEV1/FVC		0.75 (0.16)	0.85 (0.06)	<0.001
FEV1/FVC (% predicted), mean (SD)		91.71 (19.33)	102.15 (7.22)	<0.001
FEV1/FVC below LLN, n (%)		25 (39.68%)	1 (1.92%)	<0.001
MVV (L/min), Median (IQR)		54.70 (43.13-64.44)	80.40 (63.30-96.87)	<0.001
MVV (% predicted), Median (IQR)		54.99 (42.26-65.71)	67.97 (56.29-82.66)	<0.001
PEF (L/s), mean (SD)		2.58 (0.91)	5.57 (1.90)	<0.001
PEF (% predicted) , Median (IQR)		33.44 (26.62-42.53)	64.72 (52.42-73.37)	<0.001
SF-12 PCS, mean (SD)		38.22 (6.21)	40.77 (7.80)	0.050
SF-12 MCS, mean (SD)		43.01 (8.58)	45.97 (8.16)	0.057
mMRC-dyspnoea, n (%)				0.630
	2‡	61 (96.83%)	55 (98.21%)	
	3§	2 (3.17%)	1 (1.79%)	

SD, standard deviation; IQR, interquartile range

‡ On level ground, walks slower than people of same age because of breathlessness or has to stop for breath when walking at own pace.

§ Stops for breath after walking about 100 yards or after a few minutes on level ground.

Table SIX. Proportion of Missing Data for Included Variables in This Study. Data are only presented for variables with missingness greater than 1%.

Variables	Number Missing, n	Percent Missing, %
FVC (L)	4	3.36
FEV1 (L)	4	3.36
FEV1/FVC	4	3.36
MVV (L/min)	4	3.36
PEF (L/s)	4	3.36
FEV1 (% predicted)	4	3.36
FEV1 below LLN	4	3.36
FVC (% predicted)	4	3.36
FVC below LLN	4	3.36
FEV1/FVC (% predicted)	4	3.36
FEV1/FVC below LLN	4	3.36
MVV (% predicted)	4	3.36
PEF (% predicted)	4	3.36
mMRC 2 weeks	5	4.2
mMRC 4 weeks	5	4.2
Days from baseline to post-treatment assessment	7	5.88
6MWD (m), Post-treatment (6 weeks)	7	5.88
Squat time (s), Post-treatment (6 weeks)	7	5.88
SF-12 PCS, Post-treatment (6 weeks)	7	5.88
mMRC-dyspnoea, Post-treatment (6 weeks)	7	5.88
FVC (L), Post-treatment (6 weeks)	8	6.72
FEV1 (L), Post-treatment (6 weeks)	8	6.72
FEV1/FVC, Post-treatment (6 weeks)	8	6.72
MVV (L/min), Post-treatment (6 weeks)	8	6.72
PEF (L/s), Post-treatment (6 weeks)	8	6.72
FEV1 (% predicted), Post-treatment (6 weeks)	8	6.72
FVC (% predicted), Post-treatment (6 weeks)	8	6.72
FEV1/FVC (% predicted), Post-treatment (6 weeks)	8	6.72
MVV (% predicted), Post-treatment (6 weeks)	8	6.72

PEF (% predicted) , Post-treatment (6 weeks)	8	6.72
Days from baseline to follow-up assessment	14	11.76
6MWD (m), Follow-up (~28 weeks)	14	11.76
Squat time (s), Follow-up (~28 weeks)	14	11.76
SF-12 PCS, Follow-up (~28 weeks)	14	11.76
SF-12 MCS, Follow-up (~28 weeks)	14	11.76
mMRC-dyspnoea, Follow-up (~28 weeks)	14	11.76
FVC (L), Follow-up (~28 weeks)	16	13.44
FEV1 (L), Follow-up (~28 weeks)	16	13.44
FEV1/FVC, Follow-up (~28 weeks)	16	13.44
MVV (L/min), Follow-up (~28 weeks)	16	13.44
PEF (L/s), Follow-up (~28 weeks)	16	13.44
FEV1 (% predicted), Follow-up (~28 weeks)	16	13.44
FVC (% predicted), Follow-up (~28 weeks)	16	13.44
FEV1/FVC (% predicted), Follow-up (~28 weeks)	16	13.44
MVV (% predicted), Follow-up (~28 weeks)	16	13.44
PEF (% predicted) , Follow-up (~28 weeks)	16	13.44

Table SX. Comparative Analysis of Treatment Outcomes among Different Groups for the Subsequent 6 Weeks, Analyzing Data After Estimating Missing Values Using the Multiple Imputation Method.

	Subgroup	Total		Treatment without corticosteroids		Treatment with corticosteroids	
		β (95% CI)	P-Value	β (95% CI)	P-Value	β (95% CI)	P-Value
Not adjusted							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-44.10 (-82.64, -5.56)	0.025	-59.37 (-108.81, -9.92)	0.019	-30.24 (-85.79, 25.32)	0.286
	T and P 1	34.026 (-3.92, 71.98)	0.079	-19.54 (-68.23, 29.16)	0.432	105.04 (50.77, 159.31)	0.000
	C and P 1	-32.55 (-69.35, 4.25)	0.083	-47.62 (-94.16, -1.07)	0.045	-20.96 (-75.23, 33.31)	0.449
Adjusted for age, sex							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-42.81 (-81.86, -3.76)	0.031	-58.11 (-108.60, -7.61)	0.024	-30.42 (-87.29, 26.45)	0.295
	T and P 1	36.36 (-4.36, 77.08)	0.080	-15.15 (-67.01, 36.71)	0.567	103.28 (42.49, 164.07)	<0.001
	C and P 1	-28.81 (-68.92, 11.30)	0.159	-43.36 (-93.34, 6.62)	0.089	-19.42 (-82.08, 43.23)	0.543
Plus smoking history							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-45.09 (-85.01, -5.16)	0.027	-63.31 (-114.61, -12.01)	0.016	-27.50 (-86.21, 31.22)	0.359
	T and P 1	35.00 (-6.14, 76.14)	0.095	-15.56 (-67.34, 36.22)	0.556	107.02 (43.92, 170.12)	<0.001
	C and P 1	-29.84 (-70.21, 10.52)	0.147	-45.58 (-95.66, 4.50)	0.074	-17.91 (-81.30, 45.48)	0.580
Plus disease severity							

	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-46.60 (-86.71, -6.49)	0.023	-63.64 (-115.42, -11.85)	0.016	-29.57 (-88.74, 29.59)	0.327
	T and P 1	34.898 (-6.27, 76.06)	0.0967	-15.43 (-67.45, 36.59)	0.561	106.47 (43.12, 169.82)	0.001
	C and P 1	-30.48 (-70.90, 9.93)	0.139	-45.51 (-95.92, 4.89)	0.077	-19.32 (-83.04, 44.39)	0.552
Plus days from onset to admission							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-47.95 (-88.10, -7.80)	0.019	-65.09 (-117.36, -12.81)	0.015	-24.32 (-80.84, 32.19)	0.399
	T and P 1	33.18 (-8.08, 74.44)	0.115	-17.36 (-70.14, 35.41)	0.519	111.67 (51.20, 172.14)	<0.001
	C and P 1	-32.07 (-72.56, 8.41)	0.121	-46.69 (-97.50, 4.12)	0.072	-24.37 (-85.18, 36.43)	0.432
Plus length of inpatient stay							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-47.59 (-88.02, -7.16)	0.021	-64.50 (-117.37, -11.63)	0.017	-24.05 (-81.32, 33.22)	0.411
	T and P 1	33.34 (-8.10, 74.78)	0.115	-16.96 (-70.20, 36.29)	0.533	111.68 (50.54, 172.82)	<0.001
	C and P 1	-30.69 (-72.47, 11.10)	0.150	-45.63 (-97.51, 6.24)	0.085	-22.20 (-86.83, 42.42)	0.501
Plus Plus days from hospital discharge to baseline							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-46.45 (-84.56, -8.33)	0.017	-64.32 (-114.65, -13.98)	0.012	-25.80 (-81.87, 30.26)	0.367
	T and P 1	34.34 (-4.73, 73.42)	0.085	-7.90 (-59.12, 43.31)	0.762	100.25 (38.96, 161.54)	0.001
	C and P 1	-39.01 (-78.48, 0.46)	0.053	-55.78 (-105.57, -5.99)	0.028	-25.58 (-88.92, 37.75)	0.429
Plus diabetes							

	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-48.06 (-86.35, -9.76)	0.014	-64.78 (-115.50, -14.06)	0.012	-25.63 (-83.05, 31.79)	0.382
	T and P 1	33.46 (-5.66, 72.59)	0.094	-8.908 (-60.58, 42.77)	0.736	100.30 (38.13, 162.47)	0.002
	C and P 1	-38.88 (-78.37, 0.61)	0.054	-55.88 (-106.00, -5.76)	0.029	-25.65 (-89.87, 38.58)	0.434
Plus heart disease							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-48.15 (-86.64, -9.66)	0.014	-66.96 (-117.49, -16.43)	0.009	-36.50 (-91.62, 18.61)	0.194
	T and P 1	33.51 (-5.78, 72.79)	0.095	-10.06 (-61.53, 41.41)	0.702	96.852 (38.03, 155.67)	0.001
	C and P 1	-39.26 (-79.16, 0.64)	0.054	-56.01 (-105.90, -6.12)	0.028	-43.79 (-106.42, 18.83)	0.171
Plus lung disease (including inactive TB)							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-48.26 (-86.95, -9.58)	0.015	-67.30 (-118.97, -15.62)	0.011	-34.46 (-90.80, 21.87)	0.231
	T and P 1	33.39 (-6.07, 72.85)	0.097	-10.31 (-62.47, 41.84)	0.698	97.65 (38.14, 157.17)	0.001
	C and P 1	-38.74 (-79.03, 1.54)	0.060	-55.91 (-106.25, -5.57)	0.030	-40.49 (-105.16, 24.19)	0.220
Plus obesity							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-50.15 (-88.68, -11.61)	0.011	-69.89 (-120.93, -18.85)	0.007	-34.77 (-91.80, 22.26)	0.232
	T and P 1	31.01 (-8.37, 70.39)	0.123	-7.80 (-59.24, 43.64)	0.766	99.92 (38.45, 161.40)	0.001
	C and P 1	-40.56 (-80.67, -0.45)	0.048	-59.68 (-109.50, -9.85)	0.019	-40.82 (-106.30, 24.66)	0.222
Plus hypertension							

	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-49.31 (-88.69, -9.93)	0.014	-65.16 (-117.50, -12.81)	0.015	-33.47 (-91.99, 25.05)	0.262
	T and P 1	31.70 (-8.32, 71.72)	0.121	-3.538 (-56.03, 48.96)	0.895	100.83 (38.15, 163.51)	0.002
	C and P 1	-39.72 (-80.66, 1.22)	0.057	-54.36 (-105.74, -2.99)	0.038	-40.66 (-107.04, 25.72)	0.230
Plus other comorbidity							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-46.10 (-85.46, -6.75)	0.022	-64.43 (-117.08, -11.77)	0.017	-28.10 (-88.20, 32.00)	0.360
	T and P 1	30.146 (-9.75, 70.04)	0.139	-3.072 (-55.84, 49.70)	0.909	94.486 (29.65, 159.32)	0.004
	C and P 1	-41.19 (-81.96, -0.43)	0.048	-57.45 (-109.94, -4.95)	0.032	-35.82 (-103.44, 31.80)	0.299

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control; TB, Tuberculosis

Table SXI. Comparative Analysis of Treatment Outcomes among Different Groups for the Subsequent 28 Weeks, Analyzing Data After Estimating Missing Values Using the Multiple Imputation Method.

	Subgroup	Total		Treatment without corticosteroids		Treatment with corticosteroids	
		β (95% CI)	P-Value	β (95% CI)	P-Value	β (95% CI)	P-Value
Not adjusted							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-49.00 (-90.80, -7.20)	0.022	-65.99 (-121.64, -10.34)	0.020	-33.46 (-93.09, 26.17)	0.271
	T and P 1	27.47 (-13.84, 68.78)	0.193	-29.16 (-83.75, 25.43)	0.295	102.16 (41.94, 162.39)	<0.001
	C and P 1	-38.05 (-78.40, 2.30)	0.065	-56.29 (-109.28, -3.29)	0.037	-22.35 (-81.11, 36.40)	0.456
Adjusted for age, sex							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-47.30 (-89.55, -5.06)	0.028	-65.08 (-121.71, -8.44)	0.024	-30.80 (-91.53, 29.92)	0.320
	T and P 1	30.15 (-14.28, 74.57)	0.184	-27.74 (-85.66, 30.17)	0.348	108.60 (41.91, 175.29)	0.001
	C and P 1	-33.22 (-76.93, 10.49)	0.137	-54.37 (-110.53, 1.80)	0.058	-10.46 (-77.51, 56.59)	0.760
Plus smoking history							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-48.52 (-91.68, -5.37)	0.028	-70.90 (-128.13, -13.68)	0.015	-24.06 (-85.96, 37.84)	0.446
	T and P 1	29.414 (-15.56, 74.38)	0.200	-28.21 (-86.00, 29.59)	0.339	117.22 (48.49, 185.96)	<0.001
	C and P 1	-33.78 (-77.87, 10.32)	0.133	-56.85 (-112.99, -0.71)	0.047	-6.968 (-74.16, 60.22)	0.839
Plus disease severity							

	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-48.43 (-91.86, -5.00)	0.029	-70.15 (-127.91, -12.40)	0.017	-24.14 (-86.86, 38.58)	0.451
	T and P 1	29.424 (-15.73, 74.58)	0.202	-28.52 (-86.73, 29.69)	0.337	117.21 (47.76, 186.65)	<0.001
	C and P 1	-33.74 (-78.01, 10.53)	0.135	-57.00 (-113.55, -0.46)	0.048	-7.022 (-74.97, 60.93)	0.840
Plus days from onset to admission							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-51.55 (-94.23, -8.86)	0.018	-75.43 (-132.26, -18.60)	0.009	-18.12 (-76.98, 40.75)	0.546
	T and P 1	25.458 (-19.19, 70.10)	0.264	-35.50 (-93.10, 22.10)	0.227	123.16 (57.89, 188.43)	<0.001
	C and P 1	-37.39 (-80.97, 6.19)	0.093	-61.27 (-116.86, -5.68)	0.031	-12.81 (-77.11, 51.49)	0.696
Plus length of inpatient stay							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-37.00 (-101.13, 27.13)	0.258	-73.43 (-130.66, -16.19)	0.012	-18.91 (-78.22, 40.40)	0.532
	T and P 1	65.67 (-59.26, 190.60)	0.303	-34.11 (-92.05, 23.83)	0.249	123.13 (57.46, 188.80)	<0.001
	C and P 1	-28.8 (-88.00, 30.41)	0.340	-57.67 (-114.29, -1.05)	0.046	-19.17 (-86.82, 48.47)	0.579
Plus Plus days from hospital discharge to baseline							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-50.04 (-89.77, -10.30)	0.014	-73.21 (-127.00, -19.43)	0.008	-20.84 (-78.58, 36.90)	0.479
	T and P 1	26.74 (-14.92, 68.40)	0.208	-23.29 (-78.19, 31.60)	0.406	110.55 (45.79, 175.31)	<0.001
	C and P 1	-46.85 (-88.83, -4.86)	0.029	-69.78 (-123.60, -15.97)	0.011	-22.89 (-88.76, 42.97)	0.496
Plus diabetes							

	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-51.22 (-91.21, -11.22)	0.012	-73.79 (-127.95, -19.62)	0.008	-20.96 (-79.88, 37.95)	0.486
	T and P 1	26.09 (-15.70, 67.88)	0.221	-24.54 (-79.91, 30.83)	0.385	110.51 (44.96, 176.07)	0.001
	C and P 1	-46.75 (-88.85, -4.66)	0.030	-69.91 (-124.04, -15.78)	0.011	-22.85 (-89.63, 43.93)	0.503
Plus heart disease							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-51.78 (-91.71, -11.85)	0.011	-74.14 (-128.80, -19.48)	0.008	-32.73 (-88.71, 23.26)	0.252
	T and P 1	26.34 (-15.38, 68.05)	0.216	-24.73 (-80.53, 31.07)	0.385	106.78 (45.12, 168.44)	<0.001
	C and P 1	-48.97 (-91.16, -6.78)	0.023	-69.93 (-124.48, -15.38)	0.012	-42.48 (-106.82, 21.87)	0.196
Plus lung disease (including inactive TB)							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-51.65 (-91.80, -11.50)	0.012	-73.21 (-129.16, -17.26)	0.010	-31.91 (-89.43, 25.60)	0.277
	T and P 1	26.49 (-15.45, 68.43)	0.216	-24.03 (-80.57, 32.50)	0.405	107.10 (44.48, 169.72)	<0.001
	C and P 1	-49.63 (-92.01, -7.25)	0.022	-70.20 (-125.12, -15.28)	0.012	-41.16 (-108.07, 25.75)	0.228
Plus obesity							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-53.83 (-93.74, -13.93)	0.008	-75.86 (-131.26, -20.47)	0.007	-31.88 (-90.09, 26.34)	0.283
	T and P 1	23.74 (-18.04, 65.51)	0.265	-21.45 (-77.35, 34.45)	0.452	106.83 (41.37, 172.28)	0.001
	C and P 1	-51.73 (-93.86, -9.60)	0.016	-74.06 (-128.60, -19.53)	0.008	-41.12 (-108.81, 26.57)	0.234
Plus hypertension							

	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-54.77 (-95.57, -13.97)	0.009	-69.20 (-125.65, -12.75)	0.016	-37.20 (-95.88, 21.48)	0.214
	T and P 1	22.97 (-19.37, 65.31)	0.288	-15.45 (-72.02, 41.12)	0.592	103.09 (37.66, 168.52)	0.002
	C and P 1	-52.67 (-95.64, -9.70)	0.016	-66.58 (-122.36, -10.81)	0.019	-41.77 (-109.32, 25.77)	0.226
Plus other comorbidity							
	T and P 2	Ref.		Ref.		Ref.	
	C and P 2	-50.58 (-91.12, -10.03)	0.015	-67.23 (-122.88, -11.59)	0.018	-36.12 (-97.13, 24.88)	0.246
	T and P 1	20.94 (-21.04, 62.92)	0.328	-14.20 (-69.94, 41.54)	0.618	101.82 (33.98, 169.66)	0.003
	C and P 1	-54.59 (-97.16, -12.03)	0.012	-74.85 (-130.73, -18.96)	0.009	-40.80 (-110.38, 28.77)	0.250

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control; TB, Tuberculosis

Table SXII Comparative analysis of treatment outcome measure "Squat time" among different groups at Post-treatment (6 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.954			0.753			0.790
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-21.19 (-33.82, -8.56)	0.001		-25.53 (-39.01, -12.04)	< 0.001		-14.82 (-38.36, 8.72)	0.224	
	T and P 1	3.24 (-9.38, 15.87)	0.616		10.32 (-3.37, 24.01)	0.145		-5.61 (-28.65, 17.44)	0.636	
	C and P 1	-17.45 (-29.53, -5.37)	0.006		-18.07 (-30.78, -5.36)	0.007		-16.19 (-39.23, 6.85)	0.176	
Model 2				0.998			0.721			0.758
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-19.42 (-32.02, -6.81)	0.003		-24.54 (-38.27, -10.80)	< 0.001		-11.73 (-34.87, 11.42)	0.327	
	T and P 1	6.35 (-7.00, 19.71)	0.353		11.14 (-3.42, 25.71)	0.139		2.04 (-22.57, 26.65)	0.872	

	C and P 1	-13.04 (-26.02, - 0.07)	0.051		-16.62 (-30.26, - 2.99)	0.020		-5.02 (-30.45, 20.42)	0.701	
Model 3				0.927			0.281			0.602
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-19.41 (-33.24, - 5.58)	0.007		-25.07 (-39.13, - 11.02)	0.001		-5.13 (-31.67, 21.41)	0.707	
	T and P 1	4.94 (-9.43, 19.31)	0.502		11.02 (-3.74, 25.79)	0.150		0.56 (-27.54, 28.66)	0.969	
	C and P 1	-15.28 (-29.63, - 0.94)	0.040		-23.36 (-37.41, - 9.32)	0.002		3.33 (-25.96, 32.62)	0.825	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXIII. Comparative analysis of treatment outcome measure "Squat time" among different groups at Follow-up (~28 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.545			0.405			0.863
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-27.44 (-40.46, -14.43)	<0.001		-33.13 (-49.06, -17.20)	<0.001		-20.72 (-42.95, 1.52)	0.076	
	T and P 1	7.74 (-5.15, 20.63)	0.242		4.42 (-11.25, 20.09)	0.583		11.08 (-11.15, 33.32)	0.335	
	C and P 1	-14.32 (-26.61, -2.04)	0.024		-19.95 (-34.68, -5.21)	0.010		-6.96 (-28.64, 14.71)	0.533	
Model 2				0.549			0.389			0.971
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-26.58 (-39.47, -13.68)	<0.001		-32.71 (-48.79, -16.63)	<0.001		-18.22 (-40.06, 3.63)	0.111	

	T and P 1	11.80 (-1.85, 25.45)	0.093		6.02 (-10.29, 22.33)	0.472		22.26 (-2.71, 47.24)	0.089	
	C and P 1	-9.54 (-22.62, 3.54)	0.156		-17.70 (-33.23, -2.18)	0.029		4.58 (-19.51, 28.67)	0.712	
Model 3				0.651			0.896			0.174
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-25.44 (-38.75, -12.12)	< 0.001		-29.38 (-47.10, -11.67)	0.002		-16.99 (-39.69, 5.70)	0.154	
	T and P 1	10.30 (-3.40, 24.01)	0.144		10.40 (-7.35, 28.15)	0.257		9.94 (-15.66, 35.55)	0.453	
	C and P 1	-11.35 (-24.84, 2.14)	0.103		-20.34 (-37.57, -3.10)	0.026		10.56 (-14.54, 35.65)	0.417	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXIV. Comparative analysis of treatment outcome measure "SF-12 PCS" among different groups at Post-treatment (6 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.706			0.792			0.604
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-4.46 (-8.49, -0.43)	0.032		-0.54 (-5.13, 4.04)	0.817		-9.45 (-15.97, -2.94)	0.007	
	T and P 1	-0.50 (-4.53, 3.53)	0.809		3.62 (-1.03, 8.27)	0.133		-5.73 (-12.11, 0.64)	0.085	
	C and P 1	-3.92 (-7.78, -0.06)	0.049		2.26 (-2.06, 6.58)	0.309		-12.90 (-19.28, -6.52)	< 0.001	
Model 2				0.772			0.710			0.624
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-4.25 (-8.33, -0.16)	0.044		-0.25 (-4.92, 4.41)	0.916		-9.49 (-16.23, -2.75)	0.009	
	T and P 1	0.29 (-4.04, 4.62)	0.897		4.53 (-0.41, 9.48)	0.078		-5.73 (-12.89, 1.44)	0.125	

	C and P 1	-3.16 (-7.37, 1.05)	0.144		3.14 (-1.49, 7.77)	0.189		-13.05 (-20.46, - 5.65)	0.001	
Model 3				0.780			0.136			0.473
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-2.96 (-7.34, 1.41)	0.188		1.82 (-3.24, 6.88)	0.485		-8.33 (-16.43, - 0.24)	0.053	
	T and P 1	0.73 (-3.82, 5.27)	0.755		6.98 (1.66, 12.29)	0.013		-5.41 (-13.98, 3.16)	0.226	
	C and P 1	-1.46 (-6.00, 3.08)	0.531		4.14 (-0.91, 9.20)	0.115		-10.42 (-19.35, - 1.48)	0.030	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXV. Comparative analysis of treatment outcome measure "SF-12 PCS" among different groups at Follow-up (~28 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.690			0.944			0.704
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-3.70 (-9.11, 1.71)	0.183		-0.14 (-7.65, 7.37)	0.971		-7.47 (-14.65, -0.29)	0.048	
	T and P 1	0.01 (-5.34, 5.37)	0.996		4.44 (-2.95, 11.82)	0.244		-5.01 (-12.19, 2.17)	0.179	
	C and P 1	-2.22 (-7.32, 2.89)	0.397		3.95 (-3.00, 10.89)	0.270		-10.58 (-17.58, -3.59)	0.005	
Model 2				0.698			0.953			0.780
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-3.50 (-8.93, 1.94)	0.211		-0.03 (-7.67, 7.61)	0.995		-6.90 (-14.16, 0.36)	0.070	
	T and P 1	1.00 (-4.75, 6.76)	0.734		4.44 (-3.31, 12.20)	0.266		-2.46 (-10.76, 5.83)	0.564	

	C and P 1	-1.07 (-6.58, 4.45)	0.705		4.13 (-3.25, 11.50)	0.278		-7.99 (-15.99, 0.02)	0.058	
Model 3				0.450			0.572			0.678
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-3.99 (-9.51, 1.53)	0.161		0.12 (-7.62, 7.85)	0.976		-7.51 (-15.86, 0.83)	0.089	
	T and P 1	0.38 (-5.31, 6.06)	0.897		5.51 (-2.24, 13.26)	0.170		-2.55 (-11.96, 6.86)	0.600	
	C and P 1	-0.99 (-6.58, 4.61)	0.730		3.07 (-4.46, 10.59)	0.429		-8.11 (-17.33, 1.12)	0.097	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXVI. Comparative analysis of treatment outcome measure "SF-12 MCS" among different groups at Post-treatment (6 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.687			0.562			0.345
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-1.39 (-6.70, 3.92)	0.609		-2.19 (-8.32, 3.93)	0.486		-0.66 (-9.79, 8.47)	0.889	
	T and P 1	3.22 (-2.09, 8.54)	0.237		-2.51 (-8.73, 3.71)	0.432		10.45 (1.51, 19.38)	0.027	
	C and P 1	0.37 (-4.71, 5.45)	0.886		-2.31 (-8.08, 3.47)	0.437		3.94 (-5.00, 12.88)	0.393	
Model 2				0.651			0.572			0.306
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.79 (-6.13, 4.55)	0.772		-1.69 (-7.88, 4.51)	0.596		0.52 (-8.59, 9.63)	0.912	
	T and P 1	4.29 (-1.37, 9.95)	0.140		-2.37 (-8.94, 4.19)	0.481		13.77 (4.09, 23.46)	0.008	

	C and P 1	1.87 (-3.63, 7.37)	0.507		-1.76 (-7.91, 4.39)	0.577		8.16 (-1.85, 18.17)	0.118	
Model 3				0.625			0.348			0.252
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.16 (-5.95, 5.62)	0.956		-2.53 (-9.57, 4.51)	0.485		2.66 (-8.28, 13.60)	0.638	
	T and P 1	4.05 (-1.97, 10.06)	0.191		-3.70 (-11.10, 3.70)	0.332		13.94 (2.36, 25.52)	0.025	
	C and P 1	2.07 (-3.93, 8.08)	0.501		-2.17 (-9.21, 4.87)	0.548		9.40 (-2.68, 21.47)	0.138	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXVII. Comparative analysis of treatment outcome measure "SF-12 MCS" among different groups at Follow-up (~28 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.344			0.416			0.613
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.10 (-4.93, 5.14)	0.968		1.47 (-4.88, 7.82)	0.652		-1.96 (-10.17, 6.25)	0.642	
	T and P 1	5.18 (0.19, 10.16)	0.044		3.10 (-3.15, 9.35)	0.334		8.10 (-0.11, 16.31)	0.061	
	C and P 1	2.02 (-2.73, 6.77)	0.406		1.16 (-4.72, 7.03)	0.701		3.25 (-4.75, 11.25)	0.431	
Model 2				0.370			0.419			0.624
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.32 (-4.69, 5.33)	0.901		1.52 (-4.95, 7.99)	0.647		-1.39 (-9.24, 6.45)	0.730	
	T and P 1	5.84 (0.54, 11.14)	0.033		3.14 (-3.43, 9.71)	0.353		10.91 (1.94, 19.88)	0.022	

	C and P 1	3.12 (-1.96, 8.20)	0.231		1.27 (-4.98, 7.51)	0.693		6.90 (-1.75, 15.55)	0.127	
Model 3				0.318			0.758			0.157
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.84 (-4.60, 6.29)	0.762		-0.04 (-7.04, 6.96)	0.991		-0.03 (-8.75, 8.70)	0.995	
	T and P 1	6.03 (0.42, 11.64)	0.038		1.91 (-5.10, 8.93)	0.596		13.32 (3.48, 23.16)	0.013	
	C and P 1	3.45 (-2.07, 8.97)	0.224		0.61 (-6.20, 7.42)	0.861		6.23 (-3.42, 15.87)	0.217	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXVIII. Comparative analysis of treatment outcome measure "FVC" among different groups at Post-treatment (6 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.242			0.287			0.619
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.07 (-0.17, 0.30)	0.570		0.09 (-0.27, 0.45)	0.633		0.04 (-0.24, 0.33)	0.759	
	T and P 1	0.24 (0.01, 0.47)	0.041		0.29 (-0.07, 0.64)	0.118		0.19 (-0.08, 0.45)	0.184	
	C and P 1	0.12 (-0.10, 0.35)	0.273		0.12 (-0.21, 0.46)	0.479		0.14 (-0.13, 0.41)	0.327	
Model 2				0.253			0.294			0.643
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.06 (-0.18, 0.31)	0.601		0.08 (-0.29, 0.45)	0.684		0.05 (-0.24, 0.34)	0.719	
	T and P 1	0.23 (-0.02, 0.48)	0.072		0.26 (-0.12, 0.64)	0.184		0.20 (-0.10, 0.51)	0.191	

	C and P 1	0.11 (-0.13, 0.35)	0.369		0.09 (-0.27, 0.45)	0.641		0.17 (-0.14, 0.48)	0.287	
Model 3				0.356			0.571			0.470
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.07 (-0.19, 0.33)	0.587		0.08 (-0.33, 0.49)	0.703		0.08 (-0.21, 0.36)	0.609	
	T and P 1	0.23 (-0.03, 0.49)	0.088		0.21 (-0.22, 0.64)	0.335		0.05 (-0.25, 0.34)	0.770	
	C and P 1	0.15 (-0.11, 0.41)	0.259		0.15 (-0.26, 0.56)	0.467		0.24 (-0.06, 0.54)	0.131	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXIX. Comparative analysis of treatment outcome measure "FVC" among different groups at Follow-up (~28 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.905			0.323			0.193
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.04 (-0.27, 0.20)	0.762		-0.15 (-0.44, 0.15)	0.330		0.11 (-0.26, 0.49)	0.553	
	T and P 1	0.24 (0.01, 0.46)	0.042		0.18 (-0.10, 0.46)	0.212		0.32 (-0.06, 0.69)	0.106	
	C and P 1	0.18 (-0.03, 0.40)	0.095		0.22 (-0.04, 0.49)	0.106		0.09 (-0.26, 0.45)	0.606	
Model 2				0.759			0.361			0.114
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.04 (-0.27, 0.19)	0.757		-0.15 (-0.44, 0.15)	0.329		0.12 (-0.25, 0.50)	0.524	
	T and P 1	0.25 (0.01, 0.49)	0.048		0.18 (-0.12, 0.47)	0.241		0.37 (-0.07, 0.81)	0.104	

	C and P 1	0.16 (-0.07, 0.39)	0.164		0.20 (-0.08, 0.48)	0.162		0.09 (-0.32, 0.50)	0.669	
Model 3				0.937			0.368			0.651
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.02 (-0.25, 0.20)	0.838		-0.10 (-0.38, 0.18)	0.501		0.11 (-0.31, 0.54)	0.600	
	T and P 1	0.24 (0.01, 0.47)	0.042		0.20 (-0.08, 0.48)	0.161		0.19 (-0.28, 0.67)	0.431	
	C and P 1	0.21 (-0.01, 0.43)	0.071		0.25 (-0.02, 0.52)	0.072		0.20 (-0.26, 0.66)	0.396	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXX. Comparative analysis of treatment outcome measure "FEV1" among different groups at Post-treatment (6 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.605			0.243			0.452
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.07 (-0.35, 0.21)	0.631		0.15 (-0.25, 0.54)	0.468		-0.35 (-0.73, 0.02)	0.074	
	T and P 1	0.43 (0.16, 0.70)	0.002		0.47 (0.09, 0.86)	0.020		0.38 (0.02, 0.74)	0.045	
	C and P 1	0.26 (0.00, 0.52)	0.049		0.31 (-0.05, 0.68)	0.095		0.22 (-0.14, 0.57)	0.246	
Model 2				0.550			0.180			0.404
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.04 (-0.32, 0.24)	0.768		0.18 (-0.22, 0.57)	0.378		-0.34 (-0.72, 0.04)	0.091	
	T and P 1	0.49 (0.21, 0.78)	0.001		0.56 (0.16, 0.97)	0.009		0.40 (-0.00, 0.79)	0.059	

	C and P 1	0.34 (0.06, 0.62)	0.020		0.40 (0.01, 0.78)	0.049		0.26 (-0.15, 0.67)	0.218	
Model 3				0.634			0.228			0.139
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.08 (-0.38, 0.21)	0.576		0.19 (-0.23, 0.62)	0.382		-0.47 (-0.91, - 0.03)	0.046	
	T and P 1	0.49 (0.19, 0.79)	0.002		0.55 (0.11, 0.99)	0.019		0.32 (-0.14, 0.78)	0.183	
	C and P 1	0.32 (0.02, 0.62)	0.039		0.43 (0.01, 0.85)	0.052		0.24 (-0.23, 0.70)	0.329	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXXI. Comparative analysis of treatment outcome measure "FEV1" among different groups at Follow-up (~28 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.241			0.928			0.082
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.08 (-0.16, 0.32)	0.513		0.06 (-0.24, 0.37)	0.685		0.10 (-0.29, 0.50)	0.612	
	T and P 1	0.48 (0.25, 0.72)	< 0.001		0.39 (0.09, 0.68)	0.012		0.64 (0.24, 1.04)	0.003	
	C and P 1	0.37 (0.15, 0.60)	0.002		0.43 (0.16, 0.71)	0.003		0.26 (-0.12, 0.64)	0.182	
Model 2				0.147			0.808			0.069
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.10 (-0.14, 0.34)	0.426		0.07 (-0.22, 0.36)	0.626		0.11 (-0.31, 0.52)	0.617	
	T and P 1	0.56 (0.31, 0.82)	<0.001		0.47 (0.18, 0.76)	0.002		0.66 (0.18, 1.14)	0.011	

	C and P 1	0.43 (0.19, 0.67)	< 0.001		0.50 (0.22, 0.78)	<0.001		0.25 (-0.19, 0.70)	0.275	
Model 3				0.131			0.937			0.020
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.12 (-0.14, 0.39)	0.369		0.05 (-0.28, 0.39)	0.760		0.12 (-0.34, 0.59)	0.601	
	T and P 1	0.60 (0.33, 0.87)	<0.001		0.45 (0.12, 0.79)	0.010		0.77 (0.26, 1.29)	0.008	
	C and P 1	0.48 (0.22, 0.74)	< 0.001		0.52 (0.20, 0.84)	0.003		0.29 (-0.22, 0.79)	0.278	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXXII Comparative analysis of treatment outcome measure "FEV1/FVC" among different groups at Post-treatment (6 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.879			0.774			0.542
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.05 (-0.14, 0.04)	0.318		-0.00 (-0.12, 0.12)	0.993		-0.11 (-0.25, 0.03)	0.128	
	T and P 1	0.08 (-0.01, 0.17)	0.073		0.08 (-0.04, 0.20)	0.218		0.09 (-0.04, 0.22)	0.190	
	C and P 1	0.04 (-0.04, 0.13)	0.308		0.05 (-0.06, 0.17)	0.364		0.04 (-0.10, 0.17)	0.591	
Model 2				0.920			0.648			0.490
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.04 (-0.14, 0.05)	0.384		0.01 (-0.11, 0.14)	0.861		-0.12 (-0.26, 0.03)	0.117	
	T and P 1	0.10 (0.00, 0.19)	0.052		0.11 (-0.02, 0.24)	0.101		0.07 (-0.08, 0.22)	0.368	

	C and P 1	0.06 (-0.03, 0.16)	0.207		0.08 (-0.04, 0.21)	0.183		0.02 (-0.14, 0.17)	0.841	
Model 3				0.899			0.324			0.794
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	-0.06 (-0.15, 0.04)	0.255		0.02 (-0.11, 0.15)	0.725		-0.16 (-0.32, 0.00)	0.062	
	T and P 1	0.10 (0.01, 0.20)	0.042		0.13 (-0.00, 0.27)	0.061		0.11 (-0.06, 0.28)	0.225	
	C and P 1	0.04 (-0.06, 0.14)	0.439		0.08 (-0.05, 0.21)	0.239		-0.03 (-0.20, 0.14)	0.753	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.

Table SXXIII. Comparative analysis of treatment outcome measure "FEV1/FVC" among different groups at Follow-up (~28 weeks).

Estimates of treatment effects from different scenarios with 95% CI										
	Subgroup	Total		P-Value for Interaction	Treatment without corticosteroids		P-Value for Interaction	Treatment with corticosteroids		P-Value for Interaction
		β (95% CI)	P-Value		β (95% CI)	P-Value		β (95% CI)	P-Value	
Model 1				0.305			0.496			0.402
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.03 (-0.06, 0.12)	0.530		0.05 (-0.07, 0.18)	0.435		-0.00 (-0.15, 0.14)	0.991	
	T and P 1	0.10 (0.01, 0.19)	0.031		0.07 (-0.05, 0.19)	0.278		0.16 (0.01, 0.30)	0.040	
	C and P 1	0.07 (-0.02, 0.15)	0.129		0.06 (-0.05, 0.18)	0.288		0.07 (-0.06, 0.21)	0.301	
Model 2				0.275			0.450			0.485
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.03 (-0.06, 0.13)	0.489		0.05 (-0.07, 0.18)	0.408		-0.01 (-0.16, 0.14)	0.933	
	T and P 1	0.12 (0.02, 0.22)	0.024		0.09 (-0.03, 0.22)	0.151		0.14 (-0.04, 0.31)	0.137	

	C and P 1	0.08 (-0.01, 0.18)	0.095		0.09 (-0.03, 0.20)	0.163		0.06 (-0.10, 0.22)	0.488	
Model 3				0.145			0.594			0.041
	T and P 2	Ref.			Ref.			Ref.		
	C and P 2	0.04 (-0.06, 0.14)	0.474		0.04 (-0.10, 0.17)	0.597		0.00 (-0.17, 0.18)	0.977	
	T and P 1	0.14 (0.03, 0.24)	0.011		0.08 (-0.05, 0.21)	0.221		0.23 (0.03, 0.42)	0.035	
	C and P 1	0.08 (-0.02, 0.18)	0.110		0.08 (-0.05, 0.20)	0.230		0.03 (-0.17, 0.22)	0.797	

CI, confidence interval; Ref, Reference; T, TEREKO; P, Phenotype; C, Control

Model 1 is not adjusted.

Model 2 adjusted for age, sex.

Model 3 includes all variables in model 2 plus smoking history, disease severity, days from onset to admission, length of inpatient stay, days from hospital discharge to baseline and Comorbidity types.